Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy

Stuart J Schnitt

doi:10.1038/s41379-020-00665-x

Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy

Mod Pathol. 2021 Jan;34(Suppl 1):1-7. doi: 10.1038/s41379-020-00665-x. Epub 2020 Sep 9.

Author

Stuart J Schnitt^{1

2}

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. sschnitt@bwh.harvard.edu.
² Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. sschnitt@bwh.harvard.edu.

PMID: 32908254
DOI: 10.1038/s41379-020-00665-x

Abstract

Concerns about overdiagnosis and overtreatment have led to interest in de-escalating treatment for ductal carcinoma in situ (DCIS). This article reviews the epidemiology, natural history, and current treatment options for DCIS and discusses ongoing efforts to further de-escalate treatment for these patients.

Publication types

Review

MeSH terms

Breast Neoplasms / diagnosis
Breast Neoplasms / epidemiology
Breast Neoplasms / pathology
Breast Neoplasms / therapy
Carcinoma, Intraductal, Noninfiltrating* / diagnosis
Carcinoma, Intraductal, Noninfiltrating* / pathology
Carcinoma, Intraductal, Noninfiltrating* / therapy
Early Detection of Cancer
Female
Humans
Medical Overuse